The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Another chemotherapy regimen, targeted therapy, or immunotherapy
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
RECRUITINGDisease-free survival
The date of adjuvant chemotherpay initiation to tumor recurrence, local-regional or distant metastases, or death due to any cause.
Time frame: Baseline until death from any cause (up to approximately 36 months)
Overall survival
The date of adjuvant chemotherpay initiation to death due to any cause.
Time frame: Baseline until death from any cause (up to approximately 60 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.